Search - tctmd.com

Displaying 901 - 920 of 1503

Sort: Relevancy | Date

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

News Conference News ESC 2017

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

September 04, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Off-Pump CABG Linked to Higher Long-term Mortality in ROOBY

News Daily News

Off-Pump CABG Linked to Higher Long-term Mortality in ROOBY-FS

August 16, 2017

Five-Year Outcomes After On-Pump and Off-Pump Coronary-Artery Bypass

Presentation

Five-Year Outcomes After On-Pump and Off-Pump Coronary-Artery Bypass

August 16, 2017

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

Cardiac Complications of Cancer: Arterial Thromboembolism Risk Doubles With Incident Diagnosis

News Daily News

Cardiac Complications of Cancer: Arterial Thromboembolism Risk Doubles With Incident Diagnosis

Yael L. Maxwell

August 14, 2017

Obese Cardiac Surgery Patients a Burden on ICU Resources

News Daily News

Obese Cardiac Surgery Patients a Burden on ICU Resources

Michael O'Riordan

August 11, 2017

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

News Daily News

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

August 10, 2017

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

News Daily News

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

August 02, 2017

Boston Scientific Scraps Biodegradable Scaffold Program

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.